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Abstract
Background
Anxiety disorders are highly prevalent and result in low quality of life and a high social and eco-
nomic cost. The efficacy of cognitive-behavioural therapy (CBT) for anxiety disorders is well
established, but a substantial proportion of patients do not respond to this treatment. Under-
standing which genetic and environmental factors are responsible for this differential response
to treatment is a key step towards “personalizedmedicine”. Based on previous research, our
objective was to test whether theBDNFVal66Met polymorphism and/or childhoodmaltreatment
are associated with response trajectories during exposure-based CBT for panic disorder (PD).
Method
We used Growth Mixture Modeling to identify latent classes of change (response trajectories)
in patients with PD (N = 97) who underwent groupmanualized exposure-based CBT.We con-
ducted logistic regression to investigate the effect on these trajectories of the BDNF Val66Met
polymorphism and two different types of childhood maltreatment, abuse and neglect.
Results
We identified two response trajectories (“high response” and “low response”), and found
that they were not significantly associated with either the genetic (BDNF Val66Met
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Conclusions
We found no evidence to support an effect of the BDNF gene or childhood trauma-related
variables on CBT outcome in PD. Future studies in this field may benefit from looking at
other genotypes or using different (e.g. whole-genome) approaches.
Introduction
The high prevalence of the anxiety disorders is a major public health concern. Twelve-month
prevalence rates have been estimated at 18.1% in the US [1] and 13.6% in Europe [2]. In addi-
tion, anxiety disorders have a marked impact on the quality of life of those affected [3], and
cause a huge social and economic burden. At the European level, Olesen et al. [4] quantified
the total annual cost of anxiety disorders as 74.4 billion euros.
The efficacy of cognitive-behavioural therapy (CBT) for anxiety disorders is well established
from randomised controlled trials [5], and is recommended by current clinical guidelines [6,
7]. However, a substantial proportion of patients do not respond to this treatment [8], and
identifying the factors underlying this differential treatment response is now a research prior-
ity. In this context, genetic and environmental predictors of outcome have gained attention [9,
10] and will make a key contribution towards “personalized medicine” [11]. However, it
remains to be tested whether results of basic research can be translated into clinical practice.
The prediction of treatment response based on genetic background has a long history in
pharmacotherapy, but is a relatively new development in the field of psychological treatment.
The term “therapygenetics” was coined a few years ago to indicate the prediction of psychologi-
cal treatment outcomes from genetic markers [10, 12, 13]. Most research in this area has
focused on testing the effects of specific single nucleotide polymorphisms (SNP) on response to
CBT in anxiety and depressive disorders. Although the field is in its infancy, initial evidence
indicates that specific SNPs may improve the prediction of CBT outcomes (i.e. a decrease in
measures of severity). The most widely assessed SNP have been the serotonin transporter gene
functional length polymorphism (5HTTLPR), and the functional Val66Met (rs6265) polymor-
phism in the brain-derived neurotrophic factor (BDNF) gene [9, 10].
Both preclinical and clinical data suggest that Val66Met is involved in response to CBT
(and more specifically, to exposure-based interventions) for anxiety and related disorders.
Val66Met, which involves substitution of valine (Val) with methionine (Met), affects intracel-
lular trafficking and secretion of BDNF, and Met carriers show decreased activity-dependent
secretion of this neurotrophin [14]. Consistent with animal studies, this variation may be asso-
ciated with anxiety or fear in humans [15]. Recent research suggests that extinction learning,
which is the experimental model for exposure therapy, may be modulated by genetic variation
in BDNF, and both mouse and human carriers of the Met variant show impaired extinction
learning [16]. Moreover, humans carriers show a different pattern of activation of brain regions
that are essential for fear extinction (including the ventromedial prefrontal cortex and the
amygdala), which is consistent with impaired extinction learning [16, 17]. Preliminary transla-
tion of these basic results is provided by two recent studies showing that among adults with
post-traumatic stress disorder (PTSD) [18] and obsessive-compulsive disorder (OCD) [19],
those with the Met allele had a poorer response to exposure-based CBT than those with the
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Val/Val genotype. However, this association was not replicated in a study in adults with social
anxiety disorder (SAD) who received internet-based or group CBT [20], or in a study in chil-
dren with mixed anxiety disorders who were receiving CBT [21].
Regarding environmental factors, childhood maltreatment has been the focus of extensive
research. Beyond its established role as a risk factor for many mental disorders [22, 23], child-
hood maltreatment may also influence treatment outcomes. There is a well established associa-
tion between childhood maltreatment and poor response to treatment for depression, and this
association seems to be independent of treatment modality (pharmacological or psychological)
[24]. However, this issue has not been investigated in detail for anxiety disorders, and very few
studies have considered whether specific forms of maltreatment are relevant. To our knowl-
edge, only two studies in patients with SAD have examined the impact of specific types of
childhood maltreatment on CBT outcomes in anxiety disorders [25, 26]. Alden et al. [25]
found that parental abuse increased risk of poor treatment outcome, while Bruce et al. [26]
found no association between specific types of childhood maltreatment and response to CBT.
There has been at least one preliminary attempt to combine genetic and clinical variables to
predict outcomes of psychological treatment in children with anxiety disorders [9]. To our
knowledge, however, the role of genetics and early developmental experiences such as maltreat-
ment in predicting the outcome of CBT in adults has not yet been explored.
Our aim was to study whether the BDNF Val66Met polymorphism and/or childhood mal-
treatment were associated with the outcome of exposure-based CBT for panic disorder (PD) in
a naturalistic setting. Based on growth mixture models (GMM), we operationalized treatment
outcome with trajectories of change in panic symptoms. Trajectory analyses have recently been
used in psychological treatment research to identify patterns of change and to examine treat-
ment effects in different patients subgroups [27–32]. This approach has several methodological
advantages and is probably more clinically informative [28, 30, 33, 34].
Based on previous research, we predicted the existence of distinct response trajectories in
patients receiving exposure-based CBT, and we hypothetised that genetic variation (presence
of the BDNFMet allele) and childhood maltreatment (both abuse and neglect) would be associ-
ated with a less favourable response trajectory.
Method
Participants
Our sample consisted of 97 patients who completed (i.e., attended 8 sessions) a 9-week inter-
vention of manualized exposure-based group CBT (GCBT) for PD at one of two treatment cen-
tres in Barcelona (Spain) between February 2011 and January 2014. During the recruitment
period, 132 patients were assessed, and the following exclusion criteria were applied: age<18
or>60 years; presence or history of any organic mental disorder, bipolar disorder or psychosis;
substance abuse or dependence in the previous three months (except for nicotine); intellectual
disability; and language barriers. A Consort flow diagram of the recruitment process is shown
in Fig 1.
All participants had a primary diagnosis of PD (89.7% with agoraphobia) according to the
DSM-IV-TR [35], and had a score of6 on the Spanish self-report version [36] of the Panic
Disorder Severity Scale (PDSS-SR) [37]. Diagnosis was established by one experienced clinician
using a semi-structured interview, and was confirmed by another clinician using the validated
Spanish version [38] of theMini International Neuropsychiatric Interview (MINI) [39].
The final sample included 61 women (62.9%), and the mean age was 36.19 years (range 18–
60, SD = 9.23). Twenty-two participants (22.7%) presented one or more additional axis-I disor-
ders. The most common comorbidities were SAD (7.2%), specific phobia (6.2%), generalized
Trajectories during CBT for Panic Disorder: No Association with BDNF or Childhood Maltreatment
PLOS ONE | DOI:10.1371/journal.pone.0158224 June 29, 2016 3 / 14
Fig 1. Consort flow diagram.
doi:10.1371/journal.pone.0158224.g001
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anxiety disorder (3.1%), and others (6.2%). On admission, eighty-two patients (84.5%) were
taking psychiatric medication (mainly antidepressants) continually for at least two months
prior to beginning treatment, and 40 (41.2%) were taking PRN benzodiazepines. Participants
were asked to maintain their medication regime during the GCBT. Table 1 shows a demo-
graphic and clinical summary of the sample.
The study fulfilled the principles of the World Medical Association Declaration of Helsinki
and was approved by the Clinical Research Ethical Committee of the Parc de Salut Mar (Barce-
lona, Spain) and by the Clinical Research Ethical Committee of the Consorci Sanitari de Ter-
rassa (Barcelona, Spain). All participants provided voluntary informed written consent.
Assessment
The MINI (Spanish version 5.0.0) is a brief structured interview that evaluates the presence of
Axis I disorders according to DSM-IV criteria [39], and is a widely used instrument in clinical
and research settings. The Spanish version of the MINI has shown to have sound psychometric
properties [40].
Table 1. Demographic and clinical characteristics of the sample (N = 97).
% / Mean (sd)
Gender
Men 37.1%
Women 62.9%
Age (years) 36.19 (9.23)
Marital status
Single 30.5%
Married/in a relationship 69.5%
Education level
Elementary school 28.4%
High school 45.3%
University 26.3%
Unemployed 45.8%
Age of onset (panic symptoms) 25.58 (9.13)
Duration of current episode (in years) 4.13 (5.58)
Presence of agoraphobia 89.7%
Axis-I comorbidity 22.7%
Pharmacological treatment
No medication 15.5%
Antidepressant + benzodiazepine 41.2%
Antidepressant 19.6%
Benzodiazepine 23.7%
BDNF Val66Met genotypes
Val-Val 61.9%
Met carriers 38.1%
CTQ-SF scores
Emotional abuse 9.64 (5.24)
Physical abuse 6.44 (3.30)
Sexual abuse 5.69 (1.56)
Emotional neglect 10.66 (4.82)
Physical neglect 6.59 (2.46)
M = mean, sd = standard deviation, CTQ-SF = Childhood Trauma Questionnaire-Short Form
doi:10.1371/journal.pone.0158224.t001
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The self-report version of the Panic Disorder Severity Scale (PDSS-SR) is a 7-item instru-
ment that assesses the frequency of panic attacks, associated distress, anticipatory anxiety, ago-
raphobic fear and avoidance, body-sensation fear and avoidance, and impaired work and social
function [37] during the previous week. Each item is scored on a 5-point ordinal scale (0–4),
and the total score ranges between 0 and 28. The Spanish PDSS-SR has shown excellent inter-
nal consistency, good test-retest reliability, adequate convergent and divergent validity, and
good sensitivity to change [36].
The Childhood Trauma Questionnaire-Short Form (CTQ-SF) is a 28-item instrument that
measures five types of childhood maltreatment: emotional abuse, physical abuse, sexual abuse,
emotional neglect, and physical neglect [41, 42]. Each item ranges from 1 to 5, and the total
score of each subscale ranges from 5 to 25. Following previous research [43], childhood mal-
treatment was grouped into two main types: childhood abuse (including emotional, physical
and sexual abuse) and childhood neglect (including emotional and physical neglect). Child-
hood abuse and childhood neglect were calculated by summing the items of the corresponding
subscales. The Spanish CTQ-SF has been shown to be a reliable and valid instrument [44].
Treatment
Group CBT consisted of nine one-hour sessions administered on a weekly basis. Groups were
conducted by a main therapist (a PhD level clinical psychologist) and a co-therapist (a clinical
psychology trainee or psychiatric nurse), and ranged from 4 to 7 patients each. Treatment was
mannualized and the protocol was a modified version of the Panic Control Treatment by Bar-
low and Craske [45], adapted by the last author. Sessions 1 to 3 were devoted to education
about anxiety and panic; sessions 4 and 5 consisted of in-session interoceptive exposure exer-
cises, and progressive withdrawal of safety behaviors; and sessions 6 to 9 focused on graded
exposure to avoided situations and activities. The treatment included homework exercises that
varied depending on the phase of therapy, and did not include specific cognitive therapy tasks.
To maximize treatment integrity and adherence to the protocol, fortnightly meetings between
the main therapists were scheduled and checklists with the items to be covered at each session
were provided to the co-therapists. Thirty-nine patients (40.2%) had at least one individual
“booster” session during the six month follow-up period. Previous research has established the
effectiveness of this treatment protocol [46].
Procedure
At the beginning of each session and at one, three and six months follow-up, participants com-
pleted the PDSS-SR to assess panic symptoms during the previous week. Additionally, partici-
pants also completed the CTQ-SF during the initial assessment session.
Genetic analyses
Genomic DNA was extracted from buccal mucosa on a cotton swab, or from blood samples
using the Real Extraction DNA Kit (Durviz S.L.U., Valencia, Spain). The rs6265 SNP (Val66-
Met) of the BDNF gene was determined using the Taqman 5‘ exonuclease assay -Applied Bio-
systems (AB)- and genotyped using AB TaqMan technology. The probe for genotyping the
rs6265 was ordered through the TaqMan SNP Genotyping assays AB assay-on-demand service
(code C_11592758_10). The final volume of the polymerase chain reaction (PCR) reaction was
5 mL, which contained 10 ng of genomic DNA, 2.5 ml of TaqMan Master Mix, and 0.125 ml of
40x genotyping assay. The cycling parameters were as follows: 95°C for 10 min, followed by 40
cycles of denaturation at 92°C for 15 s and annealing/extension at 60°C for 1 min. PCR plates
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were read on an ABI PRISM 7900HT instrument with SDS v2.1 software (AB). The genotype
frequencies of rs6265-BDNF were in Hardy-Weinberg equilibrium (χ2 = 0.53; p = 0.467).
Statistical analyses
In the first step, we used growth mixture models (GMM) analysis to empirically identify latent
subpopulations of patients with similar change trajectories (‘trajectory classes’) in panic symp-
toms, as measured using the PDSS-SR (baseline, plus 9 weekly ratings, plus three follow-up ses-
sions). In GMM, trajectory classes are characterized by two parameters: intercept (i.e. initial
severity) and slope (i.e. rate of change). GMM allows us to test for an a priori unknown number
of latent subpopulations with different intercepts and slopes, as well as class-specific variations
around these parameters.
To determine the optimal number of trajectory classes, we compared different linear models,
starting with a one-class model (i.e. assuming that all participants followed the same trajectory)
and then adding classes in each subsequent run. For each model, allocation of individuals was
based on maximum posterior probability [47]. Models were estimated with 2000 random starting
values, using MPLUS software (version 7.0). To decide on the number of trajectory classes, we
examined the following indices of goodness of fit: Akaike Information Criterion (AIC), Bayesian
Information Criterion (BIC), sample-size adjusted BIC (SSBIC) and the bootstrap likelihood
ratio test (BLRT). The model with the lowest SSBIC was chosen [48]. The BLRT was used to
assess differences in log-likelihood between models with k and k+1 classes, where p<0.05 indi-
cates the benefit of adding an additional class [49]. We also computed the entropy value for each
class solution. In addition to the indices of goodness of fit, the optimal number of latent trajectory
classes was also based on group membership posterior probabilities, distinctiveness of classes and
how well the PDSS-SR profiles of subjects from one class matched the class average. For all inter-
cept and slope coefficients, we report unstandardized coefficients.
In the second step of the analyses, we conducted logistic regression analysis to test whether
genetic background (presence/absence of the BDNF 66Met allele) and trauma-related variables
(childhood abuse and childhood neglect) predicted class membership. To control for the
potential effect of pharmacological treatment, this variable was included in the model as a
covariate. Finally, the model also included variables for interaction effects between childhood
abuse and BDNF genotype, and between childhood neglect and BDNF gentoype.
Results
Genetic and trauma-related variables
Carriers of one or two BDNF66Met alleles were combined as a ‘‘Met-carrier group”, consistent
with previous studies [18, 19, 50]. The genotype frequencies for the BDNF Val66Met polymor-
phism were: 31.8% (N = 37) Met allele carriers (including 6 Met/Met homozygotes), and 61.9%
(N = 60) Val-Val homozygotes. In line with previous reports [51–53], we evaluated the preva-
lence of childhood maltreatment was evaluated using the following cut-off scores: emotional
abuse9, physical abuse8, sexual abuse6, emotional neglect10 and physical neglect8.
In the current sample, 53 participants (55.2%) had been exposed to at least one type (emo-
tional, physical, or sexual) of childhood abuse, and 51 (53.7%) to at least one type (emotional
or physical) of childhood neglect.
Identification of trajectory classes
Preliminary sensitivity analyses showed that the models including and excluding participants
with more than 3 missing data points gave the same class structures. Since missing data did not
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affect results substantially, two participants with missing data were excluded, leaving 95 partici-
pants for the the trajectory analyses.
Table 2 shows the fit indices for models with 1 to 3 trajectory classes for the PDSS-SR.
BLRT was only significant in the change between the 1-class and the 2-class models, which was
not significantly different to the the 3-class model. The 2-class solution was therefore selected
because it had the lowest SSBIC and a high entropy, which was 0.85, over the recommended
cut-off of 0.80 [54].
Fig 2 shows that one class (“high response”) included patients (N = 76; 80.3% of the sample)
with lower baseline panic symptoms (intercept = 12.12, SE = 2.061, p<0.01) and a tendency to
improve over time (slope = -0.329, SE = 0.12, p = 0.01). The other class (“low response”)
included patients (N = 19; 19.7% of the sample) with greater panic symptoms at baseline
Table 2. Model fit indices, p-value in Bootstrap Likelihood Ratio Test and entropy for up to three latent classes.
Model AIC BIC SSBIC BLRT difference
(number of
parameters)
p Entropy
1-class 6549.88 6629.05 6531.18 -- --
2-class 6547.61 6652.32 6522.80 23.46 (4) 0.037 0.851
3-class 6583.56 6636.18 6548.89 16.85 (4) 0.092 0.873
AIC = Akaike Information Criterion, BIC = Bayesian Information Criterion, SSBIC = sample-size adjusted BIC, BLRT = Bootstrap Likelihood Ratio Test
doi:10.1371/journal.pone.0158224.t002
Fig 2. Estimated mean scores for panic symptoms (PDSS-SR) in the two-classmodel during exposure-based CBT and follow-up.
doi:10.1371/journal.pone.0158224.g002
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(intercept = 18.36, SE = 2.76, p<0.01) and which did not improve across time (slope = -0.17,
SE = 0.15, p = 0.26).
Effects of genetic background and trauma on trajectory classes
Table 3 shows that neither the BDNF Val66Met polymorphism nor the specific types of trauma
analysed (abuse and neglect) predicted membership of any specific trajectory class. We found
no significant evidence to suggest that trajectory class membsership was affected by gene-envi-
ronment interaction between the BDNFMet allele and childhood abuse, nor between the
BDNFMet allele and childhood neglect.
Discussion
To our knowledge, this is the first study to evaluate the effects of the BDNF Val66Met polymor-
phism and childhood maltreatment as possible predictors of CBT outcome in PD (assessed
using trajectories of change). We found no evidence that either BDNF Val66Met or childhood
maltreatment were significant predictors of CBT outcome.
In our sample PD patients followed two different trajectories during treatment. Many
patients (80.3%) showed a tendency to improve as a result of CBT, whereas a significant pro-
portion (19.7%) did not. While there is a general paucity of data on trajectories of change dur-
ing CBT for PD, our results are consistent with data from a previous study that highlighted a
group of PD patients with high baseline symptoms that tend not to improve with CBT [28].
We observed a similar percentage of patients with this non-remitting course (19.7%) to that
reported by Lutz et al. (17.2%).
We did not find a significant association between the BDNF Val66Met polymorphism and
CBT treatment outcome. In light of previous reports, our results show that there is no compel-
ling evidence to suggest that this genetic variation can be used to predict response to exposure-
based CBT. In previous studies in adults, PTSD [18] and OCD patients [19] who carried the
Met allele showed a poorer response than Val/Val homozygotes, although effects of BDNF in
the OCD study were apparent in the percentage of responders, but not in the pre- to post-treat-
ment severity scores. In addition, no association has been found between the BDNFMet allele
and CBT outcome in SAD [20] or in mixed child anxiety disorders [21]. Thus, based on ours
and previous studies, it seems that the relatively well established association between the BDNF
gene and learning and memory, and specifically with fear extinction [16, 55], does not translate
easily into clinical practice. One possible explanation is that the BNDF effect may be observed
in very controlled experiments, but may be diluted among the multiple variables involved in
clinical studies [56]. In an extensive review of the association between the BDNF Val66Met
Table 3. Main effects and interactions of genetic and trauma-related variables on trajectory class membership.
B SE p
Main effects
BDNF Met allele 0.078 0.550 0.887
Childhood abuse 0.003 0.046 0.946
Childhood neglect -0.058 0.058 0.319
Interaction effects
BDNF*childhood abuse -0.060 0.098 0.544
BDNF*childhood neglect 0.059 0.123 0.631
SE = standard error
doi:10.1371/journal.pone.0158224.t003
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polymorphism and mental disorders, Notaras and van den Buuse [57] highlight some of the
possible methodological shortcomings as an explanation for previous inconsistent results,
including small sample sizes and ethnicity-specific effects. It may also be the case that the
BNDF gene provokes a poorer response in some anxiety-related disorders but not in others.
For example, Hedman et al. [12] have recently proposed that exposure might have a more deci-
sive role in some anxiety-related disorders (e.g., PTSD) than in others (e.g., SAD).
Another possibility is that other polymorphisms (rather than the one studied here) may be
more important for predicting CBT outcome. A recent large study (N = 829) did not replicate
the previously reported association [12] between the functional serotonin transporter promoter
polymorphism and CBT outcome [58]. The authors of this study recommended abandoning
the single-variant approach and moving towards a whole-genome array-based therapyge-
nomics approach. A recent study from the same group also found no evidence of an effect of
hypothalamic-pituitary-adrenal axis-related genes on response to CBT [59]. These authors also
invesitgated epigenetic factors (changes in DNAmethylation) and suggested that epigenetic
variables may be a better predictor of CBT outcome than genetic factors. Regardless, it would
be necessary to evaluate the clinical relevance of any positive association between (epi)genetic
variation and psychological treatment [21].
We also found no evidence to suggest that childhood abuse and childhood neglect predict
CBT outcome. Only two previous studies have investigated the effects of childhood maltreat-
ment on CBT outcome in anxiety disorders, specifically in SAD patients [25, 26]. Bruce et al.
did not find an association between childhood maltreatment and CBT outcome, as Alden et al.
had previoulsy observed. However, in the study by Bruce et al., the patients who reported emo-
tional abuse, emotional neglect and sexual abuse showed greater severity before and through-
out treatment. Here, we focused on symptom reduction as our index of CBT outcome, and it
remains possible that other variables (e.g. attrition rates or relapse/recurrence rates) may be
affected by childhood abuse/neglect. Future studies that include these and other treatment-
related outcomes may provide additional insights.
Finally, we detected no interaction between the polymorphism of interest and childhood
abuse or neglect. As suggested by Keers et al. [60], inconsistent findings in previous studies on
stressful life events may be due to unmeasured genetic moderators. Again, epigenetic factors
have recently been identified in individuals with a history of abuse [61] and in institutionalized
children [62], and it would be interesting for future studies to add epigenetics to the prediction
of psychological treatment outcomes.
Several limitations of this study should be noted. First, a limitation of reporting negative
results is that they could be due to a lack of statistical power rather than a real lack of effect in
the population. However, the present study reports on a larger or similar sample (N = 97) than
several previous studies that have found significant effects of genetic polymorphisms (the
BDNF Val66Met and others) on the psychological [18, 19, 63] or pharmacological treatment
[64, 65, 66] of anxiety and related disorders. Our sample is also much larger than a previous
study that did find an effect of chilldhood maltreatment on CBT outcome [25]. A formal esti-
mate of power in our study was hampered by the fact that we measured the effects of treatment
using response trajectories, and the previous literature could not offer sufficient guidance to
provide such calculations. Be as it is, one possibility to increase the sample size in future studies
would be to include patients with different anxiety-related diagnoses and/or using different
CBT modalities. This strategy was followed in Lester et al. [58], where children with mixed
anxiety disorders receiving individual CBT, group-based CBT or parent-supported guided self-
help were included. Second, most of the patients were receiving pharmacological treatment
during CBT. While medication was kept stable for at least two months before the treatment
started, we cannot exclude the possibility that improvement in panic symptoms was due to
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maintaining pharmacotherapy over time. However, this was controlled for by including drug
treatment as a covariate in our analyses. Third, our sample consisted mainly of non-responders
to pharmacotherapy, which could represent a subgroup with different (including genetic) char-
acteristics than the entire spectrum of patients with PD. Fourth, due to the low frequency of
the BDNFMet allele in the European population [67], our Met/Met group was too small to be
tested. Fifth, although we accounted for some environmental factors, the BDNF Val66Met
polymorphism is unlikely to adhere to a simple genetic model [57], and so future studies
involving genetic combinations may be warranted.
In conclusion, we found no evidence to support the effect of either the BDNF Val66Met
polymorphism or childhood trauma-related variables on CBT outcome. Future studies that
address the role of other (including epigenetic) variables may shed light on the neurobiological
prediction of psychological treatment outcomes.
Supporting Information
S1 Fig. Mean scores of the PDSS-SR throughout the treatment and follow-up for Met-carri-
ers and Val-Val.
(JPG)
Author Contributions
Conceived and designed the experiments: MS BAMAF. Performed the experiments: MS M.
Mitjans M. Montoro SR MAF. Analyzed the data: MS BA AB CGF. Wrote the paper: MS CGF
MAF. Critical revision of the manuscript for important intellectual content: BA CGF. Final
approval of the version to be published: BA AB RG VV VP CGF.
References
1. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of
12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry.
2005; 62: 617–27. PMID: 15939839
2. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. Prevalence of mental
disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders
(ESEMeD) project. Acta Psychiatr Scand Suppl. 2004;( 420): 21–7. PMID: 15128384
3. Hofmann SG, Wu JQ, Boettcher H. Effect of cognitive-behavioral therapy for anxiety disorders on qual-
ity of life: a meta-analysis. J Consult Clin Psychol. 2014; 82: 375–91. doi: 10.1037/a0035491 PMID:
24447006
4. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B; CDBE2010 study group, et al. The
economic cost of brain disorders in Europe. Eur J Neurol. 2012; 19: 155–62. doi: 10.1111/j.1468-1331.
2011.03590.x PMID: 22175760
5. Hofmann SG, Smits JA. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of
randomized placebo-controlled trials. J Clin Psychiatry. 2008; 69: 621–32. PMID: 18363421
6. American Psychiatric Association. PyschiatryOnline [Internet]. Place unknown: American Psychiatric
Association Publishing; date unknown [Accessed 2 Mar 2016]. Available: http://psychiatryonline.org/
guidelines
7. National Institute for Health and Care Excellence. NICE Guidance [Internet]. Place unknown: National
Institute for Health and Care Excellence; c2016 [Accessed 2 Mar 2016]. Available: http://www.nice.org.
uk/guidance
8. Loerinc AG, Meuret AE, Twohig MP, Rosenfield D, Bluett EJ, Craske MG. Response rates for CBT for
anxiety disorders: Need for standardized criteria. Clin Psychol Rev. 2015; 42: 72–82. doi: 10.1016/j.cpr.
2015.08.004 PMID: 26319194
9. Hudson JL, Lester KJ, Lewis CM, Tropeano M, Creswell C, Collier DA, et al. Predicting outcomes fol-
lowing cognitive behaviour therapy in child anxiety disorders: the influence of genetic, demographic
and clinical information. J Child Psychol Psychiatry. 2013; 54: 1086–94. doi: 10.1111/jcpp.12092
PMID: 23772677
Trajectories during CBT for Panic Disorder: No Association with BDNF or Childhood Maltreatment
PLOS ONE | DOI:10.1371/journal.pone.0158224 June 29, 2016 11 / 14
10. Lester KJ, Eley TC. Therapygenetics: Using genetic markers to predict response to psychological treat-
ment for mood and anxiety disorders. Biol Mood Anxiety Disord. 2013; 3: 4. doi: 10.1186/2045-5380-3-
4 PMID: 23388219
11. National Institute of Health. National Institute of Mental Health Strategic Plan for Reserarch [Internet].
Place unknown: National Institute of Health; 2015 [Accessed 2 Mar 2016]. Available: http://www.nimh.
nih.gov/about/strategic-planning-reports/nimh_strategicplanforresearch_508compliant_corrected_
final_149979.pdf
12. Eley TC, Hudson JL, Creswell C, Tropeano M, Lester KJ, Cooper P, et al. Therapygenetics: the
5HTTLPR and response to psychological therapy. Mol Psychiatry. 2012; 17: 236–7. doi: 10.1038/mp.
2011.132 PMID: 22024766
13. Eley TC. The future of therapygenetics: where will studies predicting psychological treatment response
from genomic markers lead? Depress Anxiety. 2014; 31: 617–20. doi: 10.1002/da.22292 PMID:
25044231
14. Chen ZY, Patel PD, Sant G, Meng CX, Teng KK, Hempstead BL, et al. Variant brain-derived neuro-
trophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-
type BDNF in neurosecretory cells and cortical neurons. J Neurosci. 2004; 24: 4401–11. PMID:
15128854
15. Domingos da Silveira da Luz AC, Pereira Dias G, Bevilaqua MC do Nascimento, Cocks G, Gardino PF,
Thuret S, et al. Translational findings on brain-derived neurotrophic factor and anxiety: contributions
from basic research to clinical practice. Neuropsychobiology. 2013; 68: 129–38. doi: 10.1159/
000353269 PMID: 24051499
16. Soliman F, Glatt CE, Bath KG, Levita L, Jones RM, Pattwell SS, et al. A genetic variant BDNF polymor-
phism alters extinction learning in both mouse and human. Science. 2010; 327: 863–6. doi: 10.1126/
science.1181886 PMID: 20075215
17. Lonsdorf TB, Golkar A, Lindstrom KM, Haaker J, Ohman A, Schalling M, et al. BDNFval66met affects
neural activation pattern during fear conditioning and 24 h delayed fear recall. Soc Cogn Affect Neu-
rosci. 2015; 10: 664–71. doi: 10.1093/scan/nsu102 PMID: 25103087
18. Felmingham KL, Dobson-Stone C, Schofield PR, Quirk GJ, Bryant RA. The brain-derived neurotrophic
factor Val66Met polymorphism predicts response to exposure therapy in posttraumatic stress disorder.
Biol Psychiatry. 2013; 73: 1059–63. doi: 10.1016/j.biopsych.2012.10.033 PMID: 23312562
19. Fullana MA, Alonso P, Gratacos M, Jaurrieta N, Jimenez-Murcia S, Segalas C, et al. Variation in the
BDNF Val66Met polymorphism and response to cognitive-behavior therapy in obsessive-compulsive
disorder. Eur Psychiatry. 2012; 27: 386–90. doi: 10.1016/j.eurpsy.2011.09.005 PMID: 22153732
20. Hedman E, Andersson E, Ljotsson B, Andersson G, Andersson E, Schalling M, et al. Clinical and
genetic outcome determinants of Internet- and group-based cognitive behavior therapy for social anxi-
ety disorder. Acta Psychiatr Scand. 2012; 126: 126–36. doi: 10.1111/j.1600-0447.2012.01834.x PMID:
22320999
21. Lester KJ, Hudson JL, Tropeano M, Creswell C, Collier DA, Farmer A, et al. Neurotrophic gene poly-
morphisms and response to psychological therapy. Transl Psychiatry. 2012; 2: e108. doi: 10.1038/tp.
2012.33 PMID: 22832952
22. Hovens JG, Giltay EJ, van Hemert AM, Penninx BW. ChildhoodMaltreatment and the Course of
Depressive and Anxiety Disorders: The Contribution of Personality Characteristics. Depress Anxiety.
2016; 33: 27–34. doi: 10.1002/da.22429 PMID: 26418232
23. Lereya ST, CopelandWE, Costello EJ, Wolke D. Adult mental health consequences of peer bullying
and maltreatment in childhood: two cohorts in two countries. Lancet Psychiatry. 2015; 2: 524–31. doi:
10.1016/S2215-0366(15)00165-0 PMID: 26360448
24. Nanni V, Uher R, Danese A. Childhood maltreatment predicts unfavorable course of illness and treat-
ment outcome in depression: a meta-analysis. Am J Psychiatry. 2012; 169: 141–51. PMID: 22420036
25. Alden LE, Taylor CT, Laposa JM, Mellings TMB. Impact of social developmental experiences on cogni-
tive-behavioral therapy for generalized social phobia. J Cogn Psychother. 2006; 20: 7–16.
26. Bruce LC, Heimberg RG, Goldin PR, Gross JJ. Childhood maltreatment and response to cognitive
behavioral therapy among individuals with social anxiety disorder. Depress Anxiety. 2013; 30: 662–9.
doi: 10.1002/da.22112 PMID: 23554134
27. Wardenaar KJ, Conradi HJ, de Jonge P. Data-driven course trajectories in primary care patients with
major depressive disorder. Depress Anxiety. 2014; 31: 778–86. doi: 10.1002/da.22228 PMID:
24390862
28. Lutz W, Hofmann SG, Rubel J, Boswell JF, Shear MK, Gorman JM, et al. Patterns of early change and
their relationship to outcome and early treatment termination in patients with panic disorder. J Consult
Clin Psychol. 2014; 82: 287–97. doi: 10.1037/a0035535 PMID: 24447004
Trajectories during CBT for Panic Disorder: No Association with BDNF or Childhood Maltreatment
PLOS ONE | DOI:10.1371/journal.pone.0158224 June 29, 2016 12 / 14
29. Joesch JM, Golinelli D, Sherbourne CD, Sullivan G, Stein MB, Craske MG, et al. Trajectories of change
in anxiety severity and impairment during and after treatment with evidence-based treatment for multi-
ple anxiety disorders in primary care. Depress Anxiety. 2013; 30: 1099–106. doi: 10.1002/da.22149
PMID: 23801589
30. Stulz N, Thase ME, Klein DN, Manber R, Crits-Christoph P. Differential effects of treatments for chronic
depression: a latent growth model reanalysis. J Consult Clin Psychol. 2010; 78: 409–19. doi: 10.1037/
a0019267 PMID: 20515216
31. Stulz N, Lutz W. Multidimensional patterns of change in outpatient psychotherapy: the phase model
revisited. J Clin Psychol. 2007; 63: 817–33. PMID: 17674397
32. Sunderland M, Wong N, Hilvert-Bruce Z, Andrews G. Investigating trajectories of change in psychologi-
cal distress amongst patients with depression and generalised anxiety disorder treated with internet
cognitive behavioural therapy. Behav Res Ther. 2012; 50: 374–80. doi: 10.1016/j.brat.2012.03.005
PMID: 22498311
33. Nagin DS. Group-based trajectory modeling: an overview. Ann Nutr Metab. 2014; 65: 205–10. doi: 10.
1159/000360229 PMID: 25413659
34. Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol.
2010; 6: 109–38. doi: 10.1146/annurev.clinpsy.121208.131413 PMID: 20192788
35. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR.
4th ed., text revision. Washington, DC: American Psychiatric Association; 2000.
36. Santacana M, Fullana MA, Bonillo A, Morales M, Montoro M, Rosado S, et al. Psychometric properties
of the Spanish self-report version of the panic disorder severity scale. Compr Psychiatry. 2014; 55:
1467–72. doi: 10.1016/j.comppsych.2014.04.007 PMID: 24850072
37. Houck PR, Spiegel DA, Shear MK, Rucci P. Reliability of the self-report version of the panic disorder
severity scale. Depress Anxiety. 2002; 15: 183–5. PMID: 12112724
38. Bobes J, García-Portilla MP, Bascarán MT, Sáiz PA, Bousoño M. Banco de instrumentos básicos para
la práctica de la psiquiatria clínica (Collection of basic tools for the practice of clinical psychiatry). 2nd
ed. Barcelona, Spain: Psiquiatría Editores; 2002.
39. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International
Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychi-
atric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59(Suppl 20): 22–33. PMID: 9881538
40. Bobes J. A Spanish validation study of the Mini International Neuropsychiatric Interview. Eur Psychia-
try. 1998; 13: 198–9. doi: 10.1016/S0924-9338(98)80004-7
41. Bernstein DP, Fink L, Handelsman L, Foote J, Lovejoy M, Wenzel K, et al. Initial reliability and validity of
a new retrospective measure of child abuse and neglect. Am J Psychiatry. 1994; 151: 1132–6. PMID:
8037246
42. Bernstein DP, Stein JA, Newcomb MD, Walker E, Pogge D, Ahluvalia T, et al. Development and valida-
tion of a brief screening version of the Childhood Trauma Questionnaire. Child Abuse Negl. 2003; 27:
169–90. PMID: 12615092
43. Alemany S, Arias B, Aguilera M, Villa H, Moya J, Ibanez MI, et al. Childhood abuse, the BDNF-Val66-
Met polymorphism and adult psychotic-like experiences. Br J Psychiatry. 2011; 199: 38–42. doi: 10.
1192/bjp.bp.110.083808 PMID: 21719879
44. Hernandez A, Gallardo-Pujol D, Pereda N, Arntz A, Bernstein DP, Gaviria AM, et al. Initial validation of
the Spanish childhood trauma questionnaire-short form: factor structure, reliability and association with
parenting. J Interpers Violence. 2013; 28: 1498–518. doi: 10.1177/0886260512468240 PMID:
23266990
45. Craske M.G, Barlow DH. Mastery of your Anxiety and Panic. Therapist Guide. 4th ed. New York:
Oxford University Press; 2007.
46. Prats E, Dominguez E, Rosado S, Pailhez G, Bulbena A, Fullana MA. Effectiveness of cognitive-behav-
ioral group therapy for panic disorder in a specialized unit. Actas Esp Psiquiatr. 2014; 42: 176–84.
PMID: 25017495
47. Muthén B. Latent variable mixture modeling. In: Marcoulides GA, Schumacker RE, editors. New Devel-
opments and Techniques in Structural Equation Modeling. Mahwah, NJ: Lawrence Erlbaum Associ-
ates; 2001. pp. 1–33.
48. Nylund KL, Asparouhov T, Muthén BO. Deciding on the number of classes in talent class analysis and
growth mixture modeling: a Monte Carlo simulation study. Struct Equ Model. 2007; 14: 535–69.
49. McLachlan G, Peel D. Finite mixture models. New York, NY: Wiley; 2004.
50. Lonsdorf TB, Weike AI, Golkar A, Schalling M, HammAO, Ohman A. Amygdala-dependent fear condi-
tioning in humans is modulated by the BDNFval66met polymorphism. Behav Neurosci. 2010; 124: 9–
15. doi: 10.1037/a0018261 PMID: 20141276
Trajectories during CBT for Panic Disorder: No Association with BDNF or Childhood Maltreatment
PLOS ONE | DOI:10.1371/journal.pone.0158224 June 29, 2016 13 / 14
51. Tietjen GE, Brandes JL, Peterlin BL, Eloff A, Dafer RM, Stein MR, et al. Childhoodmaltreatment and
migraine (part I). Prevalence and adult revictimization: a multicenter headache clinic survey. Headache.
2010; 50: 20–31. doi: 10.1111/j.1526-4610.2009.01556.x PMID: 19845782
52. Li X, Wang Z, Hou Y, Wang Y, Liu J, Wang C. Effects of childhood trauma on personality in a sample of
Chinese adolescents. Child Abuse Negl. 2014; 38: 788–96. doi: 10.1016/j.chiabu.2013.09.002 PMID:
24161247
53. Schulz A, Schmidt CO, Appel K, Mahler J, Spitzer C, Wingenfeld K, et al. Psychometric functioning,
socio-demographic variability of childhood maltreatment in the general population and its effects of
depression. Int J Methods Psychiatr Res. 2014; 23: 387–400. doi: 10.1002/mpr.1447 PMID: 24990306
54. Clark SL. Mixture modeling with behavioral data. Doctoral dissertation, University of California. 2010.
Available: http://www.statmodel.com/download/Dissertation_v1.pdf
55. Yu H, Wang Y, Pattwell S, Jing D, Liu T, Zhang Y, et al. Variant BDNF Val66Met polymorphism affects
extinction of conditioned aversive memory. J Neurosci. 2009; 29: 4056–64. doi: 10.1523/JNEUROSCI.
5539-08.2009 PMID: 19339601
56. Craske MG, Roy-Byrne PP, Stein MB, Sullivan G, Sherbourne C, Bystritsky A. Treatment for anxiety
disorders: Efficacy to effectiveness to implementation. Behav Res Ther. 2009; 47: 931–7. doi: 10.1016/
j.brat.2009.07.012 PMID: 19632667
57. Notaras M, Hill R, van den Buuse M. The BDNF gene Val66Met polymorphism as a modifier of psychi-
atric disorder susceptibility: progress and controversy. Mol Psychiatry. 2015; 20: 916–30. doi: 10.1038/
mp.2015.27 PMID: 25824305
58. Lester KJ, Roberts S, Keers R, Coleman JR, Breen G, Wong CC, et al. Non-replication of the associa-
tion between 5HTTLPR and response to psychological therapy for child anxiety disorders. Br J Psychi-
atry. 2016; 208: 182–8. doi: 10.1192/bjp.bp.114.154997 PMID: 26294368
59. Roberts S, Keers R, Lester KJ, Coleman JR, Breen G, Arendt K, et al. Hpa Axis Related Genes and
Response to Psychological Therapies: Genetics and Epigenetics. Depress Anxiety. 2015; 32: 861–70.
doi: 10.1002/da.22430 PMID: 26647360
60. Keers R, Uher R, Huezo-Diaz P, Smith R, Jaffee S, Rietschel M, et al. Interaction between serotonin
transporter gene variants and life events predicts response to antidepressants in the GENDEP project.
Pharmacogenomics J. 2011; 11: 138–45. doi: 10.1038/tpj.2010.14 PMID: 20212518
61. Labonte B, SudermanM, Maussion G, Navaro L, Yerko V, Mahar I, et al. Genome-wide epigenetic reg-
ulation by early-life trauma. Arch Gen Psychiatry. 2012; 69: 722–31. doi: 10.1001/archgenpsychiatry.
2011.2287 PMID: 22752237
62. Naumova OY, Lee M, Koposov R, Szyf M, Dozier M, Grigorenko EL. Differential patterns of whole-
genome DNAmethylation in institutionalized children and children raised by their biological parents.
Dev Psychopathol. 2012; 24: 143–55. doi: 10.1017/S0954579411000605 PMID: 22123582
63. Knuts I, Esquivel G, Kenis G, Overbeek T, Leibold N, Goossens L, Schruers K. Therapygenetics: 5-
HTTLPR genotype predicts the response to exposure therapy for agoraphobia. Eur Neuropsychophar-
macol. 2014; 24: 1222–8 doi: 10.1016/j.euroneuro.2014.05.007 PMID: 24906789
64. Stein MB, Seedat S, Gelernter J. Serotonin transporter gene promoter polymorphism predicts SSRI
response in generalized social anxiety disorder. Psychopharmacology (Berl). 2006; 187: 68–72.
65. Perna G, Favaron E, Di Bella D, Bussi R, Bellodi L. Antipanic efficacy ofparoxetine and polymorphism
within the promoter of the serotonintransporter gene. Neuropsychopharmacology. 2005; 30: 2230–
2235. PMID: 16034444
66. Ishiguro S, Watanabe T, Ueda M, Saeki Y, Hayashi Y, Akiyama K, et al. Determinants of pharmacody-
namic trajectory of the therapeutic response toparoxetine in Japanese patients with panic disorder. Eur
J Clin Pharmacol. 2011; 67: 1213–1221. doi: 10.1007/s00228-011-1073-9 PMID: 21688171
67. Petryshen TL, Sabeti PC, Aldinger KA, Fry B, Fan JB, Schaffner SF, et al. Population genetic study of
the brain-derived neurotrophic factor (BDNF) gene. Mol Psychiatry. 2010; 15: 810–5. doi: 10.1038/mp.
2009.24 PMID: 19255578
Trajectories during CBT for Panic Disorder: No Association with BDNF or Childhood Maltreatment
PLOS ONE | DOI:10.1371/journal.pone.0158224 June 29, 2016 14 / 14
